[go: up one dir, main page]

AR091116A1 - Anticuerpos biespecificos y sus metodos de uso - Google Patents

Anticuerpos biespecificos y sus metodos de uso

Info

Publication number
AR091116A1
AR091116A1 ARP130101765A AR091116A1 AR 091116 A1 AR091116 A1 AR 091116A1 AR P130101765 A ARP130101765 A AR P130101765A AR 091116 A1 AR091116 A1 AR 091116A1
Authority
AR
Argentina
Prior art keywords
methods
bispecific antibodies
binding entity
bispecific
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
C Wong Susan
B Hamacher Nels
Gao Mian
Chakraborty Indrani
Sheriff Steven
Ditto Noah
A Schneeweis Lumelle
m cardarelli Josephine
Chen Guodong
Wei Hui
R Krystek Stanley
Edwards Thomas
O Sheppard Paul
Atkins Kateri
Arakaki Tracy
L Stevens Brenda
Witte Alison
R Presnell Scott
Srinivasan Mohan
W Rixon Mark
D Kempe Thomas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR091116A1 publication Critical patent/AR091116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antagonización de la actividad de IL-17a (IL = interleuquina), IL-17F e IL-23 usando anticuerpos biespecíficos que comprenden una entidad de fijación que tiene reactividad cruzada con IL-17A e IL-17F, y una entidad de fijación que se fija a IL-23p19. Formatos de anticuerpos biespecíficos y sus métodos de uso. Ácido nucleico, vector, célula, método para producir el anticuerpo, composición.
ARP130101765 2012-05-22 2013-05-21 Anticuerpos biespecificos y sus metodos de uso AR091116A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650286P 2012-05-22 2012-05-22
US201361784600P 2013-03-14 2013-03-14
US201361787890P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR091116A1 true AR091116A1 (es) 2015-01-14

Family

ID=48539425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101765 AR091116A1 (es) 2012-05-22 2013-05-21 Anticuerpos biespecificos y sus metodos de uso

Country Status (11)

Country Link
US (8) US9708401B2 (es)
EP (2) EP3456741B1 (es)
JP (1) JP6362587B2 (es)
CN (1) CN104884473B (es)
AR (1) AR091116A1 (es)
ES (2) ES2711554T3 (es)
LT (1) LT2852615T (es)
SI (1) SI2852615T1 (es)
TW (1) TWI609882B (es)
UY (1) UY34815A (es)
WO (1) WO2013177101A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009534297A (ja) 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2015231256A1 (en) 2014-03-19 2016-09-22 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
PL3142750T3 (pl) * 2014-05-13 2021-03-08 The Trustees Of The University Of Pennsylvania Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
WO2016014761A1 (en) * 2014-07-24 2016-01-28 Academia Sinica Diagnosis and treatment of kawasaki disease
JP6313530B1 (ja) * 2015-01-16 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 標的化成分及びエフェクター成分を有する分子構築物
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
BR112017025297A2 (pt) 2015-06-03 2018-08-14 Bristol-Myers Squibb Company anticorpos anti-gitr para diagnóstico do câncer
CA2986066A1 (en) * 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
EA201890360A1 (ru) * 2015-07-23 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
BR112018004536A2 (pt) 2015-09-09 2018-12-11 Blaze Bioscience Inc peptídeos de endereçamento à cartilagem
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
AU2017328310B2 (en) * 2016-09-14 2020-10-15 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to IL-17A and functional fragment thereof
KR102321861B1 (ko) * 2017-03-10 2021-11-05 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
JP7280193B2 (ja) * 2017-03-16 2023-05-23 ブレイズ バイオサイエンス， インコーポレイテッド 軟骨ホーミングペプチドコンジュゲート及びその使用方法
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CN107384960B (zh) * 2017-07-25 2020-06-12 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
AU2018361975A1 (en) 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN108929903B (zh) * 2018-04-23 2021-07-16 东莞市第五人民医院(东莞市太平人民医院) 用于慢性牙周炎筛查、诊断、疗效评价的标志物及试剂盒
TWI779253B (zh) * 2018-11-27 2022-10-01 大陸商信達生物製藥（蘇州）有限公司 抗IL-23p19抗體及其用途
WO2020132574A1 (en) * 2018-12-21 2020-06-25 CentryMed Pharmaceutical Inc. Protease cleavable bispecific antibodies and uses thereof
CN110330566A (zh) * 2019-06-11 2019-10-15 南京华岩生物技术有限公司 一种具有双重可变结构域的双特异性结合的免疫球蛋白
EP4142739A2 (en) 2020-04-27 2023-03-08 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
JP2025516772A (ja) 2022-05-16 2025-05-30 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いて巨細胞性動脈炎を治療する方法
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
WO2025245150A1 (en) * 2024-05-20 2025-11-27 The Trustees Of Columbia University In The City Of New York Anti-pd-1 x il-25 bispecific antibody to treat cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO1999054357A1 (en) 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
TR200603997T1 (tr) 1999-03-25 2010-01-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US20030199041A1 (en) 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
EP2857516B1 (en) * 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
TWI385180B (zh) * 2003-07-15 2013-02-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
CN1914311B (zh) 2003-12-09 2011-05-04 诺维信股份有限公司 消除或减少丝状真菌菌株基因表达的方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GT200600065A (es) 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
KR20080099290A (ko) 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
JP2009534297A (ja) 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
ES2373069T3 (es) 2006-08-11 2012-01-31 Schering Corporation Anticuerpos para il-17a.
JP5116842B2 (ja) * 2007-04-27 2013-01-09 ザイモジェネティクス， インコーポレイテッド ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法
CA2683145C (en) * 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
CN101842387B (zh) * 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2281845B1 (en) 2008-04-25 2020-09-02 Kyowa Kirin Co., Ltd. Stable polyvalent antibody
JP2011519911A (ja) 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
TW201008580A (en) * 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
SG10201402960SA (en) 2009-03-05 2014-08-28 Abbvie Inc IL-17 Binding Proteins
AU2011282476B2 (en) * 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof

Also Published As

Publication number Publication date
LT2852615T (lt) 2019-02-11
EP3456741B1 (en) 2020-12-16
TW201350503A (zh) 2013-12-16
UY34815A (es) 2013-11-29
JP6362587B2 (ja) 2018-07-25
ES2711554T3 (es) 2019-05-06
US8945553B2 (en) 2015-02-03
EP3456741A1 (en) 2019-03-20
WO2013177101A3 (en) 2014-05-15
CN104884473A (zh) 2015-09-02
EP2852615B1 (en) 2018-12-05
US10358489B2 (en) 2019-07-23
US9783606B2 (en) 2017-10-10
ES2846623T3 (es) 2021-07-28
CN104884473B (zh) 2019-12-03
US20170022272A1 (en) 2017-01-26
US11254740B2 (en) 2022-02-22
US20200040072A1 (en) 2020-02-06
US20130315911A1 (en) 2013-11-28
US20150086552A1 (en) 2015-03-26
EP2852615A2 (en) 2015-04-01
JP2015520169A (ja) 2015-07-16
US20150099278A1 (en) 2015-04-09
TWI609882B (zh) 2018-01-01
US20220185877A1 (en) 2022-06-16
US20180037645A1 (en) 2018-02-08
SI2852615T1 (sl) 2019-02-28
WO2013177101A2 (en) 2013-11-28
US9708401B2 (en) 2017-07-18
US10358490B2 (en) 2019-07-23
US20170275357A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
AR091116A1 (es) Anticuerpos biespecificos y sus metodos de uso
ES2560470T3 (es) Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
PE20190229A1 (es) Anticuerpos anti-fcrn
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
EA201400709A1 (ru) Молекула биспецифического антитела
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
AR094872A1 (es) Anticuerpos anti-tnf-anti-il-17 biespecíficos
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
MX374976B (es) Anticuerpos y metodos de uso.
AR096713A1 (es) Proceso de purificación para anticuerpos monoclonales
MX384138B (es) Anticuerpos anti-c5 y métodos para su uso.
MX2015010522A (es) Receptor de antígeno químerico y métodos para usarlo.
CL2015000757A1 (es) Una proteina
PH12015502819A1 (en) Anti-pd-1 antibody and use thereof
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
MX370651B (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX2014007262A (es) Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure